Jade Biosciences, Inc. (JBIO)
NASDAQ:JBIO
Want to see JBIO full AI Analyst Report?
Top Page
Jade Biosciences
(NASDAQ:JBIO)
Select Model
Select Model
Rating:47Neutral
Price Target:
$15.00
▼(-34.35% Downside)
Action:Reiterated
Date:06/12/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and substantial cash burn) and bearish technical trend signals despite oversold readings. Offsetting factors include a low-leverage balance sheet and positive pipeline/financing corporate updates (Phase 1 progress and a major equity raise improving funding runway), but valuation support is limited due to negative earnings and no dividend.
Positive Factors
Low leverage / sizable equity base
Debt-to-equity near 0.2% and substantial assets/equity provide durable solvency and financial flexibility. This structural strength lowers default risk and gives management room to fund R&D and trials without immediate reliance on costly debt, supporting multi-quarter program execution.
Negative Factors
Pre-revenue business model
With no product revenue, the company remains fully reliant on external capital to fund operations. Persistent, widening operating losses mean internal cash generation is insufficient, creating structural dependence on financings until a commercial product or partnering revenue is realized.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / sizable equity base
Debt-to-equity near 0.2% and substantial assets/equity provide durable solvency and financial flexibility. This structural strength lowers default risk and gives management room to fund R&D and trials without immediate reliance on costly debt, supporting multi-quarter program execution.
Read all positive factors
Jade Biosciences (JBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$933.59M
Dividend Yield14.68%
Average Volume (3M)895.06K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue GrowthN/A
EPS Growth94.97%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.92
Shares Outstanding60,859,875
10 Day Avg. Volume1,663,497
30 Day Avg. Volume895,057
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-70.23K
Enterprise Value/Ebitda-4.88
Forecast
1Y Price Target
$48.50Price Target Upside112.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.66
Revenue Forecast (FY)N/A
Jade Biosciences Business Overview & Revenue Model
Company Description
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specific...
How the Company Makes Money
null...
Jade Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.00K | 0.00 | -282.00K | -96.00K | -68.00K | -15.00K |
| EBITDA | -129.50M | -127.33M | -69.29M | -75.37M | -51.42M | -22.95M |
| Net Income | -129.61M | -127.41M | -69.63M | -75.52M | -51.51M | -22.96M |
Balance Sheet | ||||||
| Total Assets | 319.43M | 349.78M | 80.33M | 127.42M | 135.30M | 175.36M |
| Cash, Cash Equivalents and Short-Term Investments | 311.30M | 336.16M | 78.62M | 122.44M | 129.22M | 167.38M |
| Total Debt | 679.00K | 724.00K | 417.00K | 675.00K | 1.09M | 574.00K |
| Total Liabilities | 22.97M | 17.26M | 3.90M | 17.96M | 8.56M | 2.94M |
| Stockholders Equity | 296.46M | 332.52M | 76.43M | 109.46M | 126.74M | 172.42M |
Cash Flow | ||||||
| Free Cash Flow | -116.58M | -94.89M | -71.20M | -56.92M | -39.32M | -27.58M |
| Operating Cash Flow | -116.39M | -94.69M | -71.20M | -56.78M | -39.12M | -27.40M |
| Investing Cash Flow | -268.33M | -247.01M | 56.03M | 11.88M | 6.93M | -113.43M |
| Financing Cash Flow | 359.97M | 360.77M | 25.43M | 46.00M | 396.00K | 190.46M |
Jade Biosciences Technical Analysis
Negative
22.85
Price Trends
21.20
Negative
17.92
Negative
14.48
Positive
Market Momentum
-1.90
Positive
30.18
Neutral
20.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JBIO, the sentiment is Negative. The current price of 22.85 is above the 20-day moving average (MA) of 19.34, above the 50-day MA of 21.20, and above the 200-day MA of 14.48, indicating a neutral trend. The MACD of -1.90 indicates Positive momentum. The RSI at 30.18 is Neutral, neither overbought nor oversold. The STOCH value of 20.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JBIO.
Jade Biosciences Risk Analysis
Jade Biosciences disclosed 74 risk factors in its most recent earnings report. Jade Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jade Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $571.36M | -6.81 | -32.33% | ― | ― | 38.99% | |
49 Neutral | $234.23M | -2.14 | -2781.56% | ― | 289.94% | 16.60% | |
47 Neutral | $933.59M | -6.84 | -51.34% | 14.68% | ― | 94.97% | |
46 Neutral | $231.85M | -4.79 | -80.61% | ― | 43.21% | -15.55% | |
41 Neutral | $175.84M | -6.69 | 21.05% | ― | ― | 43.38% | |
40 Underperform | $49.01M | -0.82 | -69.20% | ― | ― | -69.60% |
* Healthcare Sector Average
JBIO
Jade Biosciences
15.34
8.35
119.46%
GALT
Galectin Therapeutics
2.67
1.18
79.19%
IMMP
Immutep
0.36
-1.35
-78.77%
CLLS
Cellectis SA
3.09
1.71
123.91%
TECX
Tectonic Therapeutic
30.28
8.73
40.51%
HUMA
Humacyte
1.06
-1.36
-56.22%
Jade Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Jade Biosciences Shareholders Approve Governance and Audit Measures
Positive
Jun 11, 2026
Jade Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, where shareholders elected two Class II directors, Christopher Cain, Ph.D., and Tom Frohlich, to serve on the board until the 2029 Annual Meeting. Stockholders al...
Business Operations and StrategyPrivate Placements and Financing
Jade Biosciences Launches Major Underwritten Equity Offering
Positive
Jun 4, 2026
On June 3, 2026, Jade Biosciences, Inc. entered into an underwriting agreement with a syndicate led by Jefferies, TD Securities and UBS for an underwritten public offering of 10,000,000 common shares at $15.00 each, with underwriters purchasing at...
Business Operations and StrategyProduct-Related Announcements
Jade Biosciences Reports Positive Phase 1 JADE101 Results
Positive
Jun 1, 2026
On June 1, 2026, Jade Biosciences reported interim results from a Phase 1 double-blind, placebo-controlled trial of JADE101 in 32 healthy volunteers, showing single subcutaneous doses up to 1,400 mg were well tolerated with no serious adverse even...
Executive/Board Changes
Jade Biosciences Elevates Andrew King to R&D President
Neutral
Apr 22, 2026
On April 18, 2026, Jade Biosciences, Inc. appointed Andrew King, BVMS, Ph.D. as President, Research Development, formalizing his leadership over the company’s scientific programs. Dr. King, who previously served as Chief Scientific Officer ...
Business Operations and Strategy
Jade Biosciences Adopts 2026 Employment Inducement Stock Plan
Positive
Apr 2, 2026
On March 31, 2026, Jade Biosciences, Inc.’s board approved the 2026 Employment Inducement Stock Incentive Plan, modeled largely on its 2025 Stock Incentive Plan but excluding incentive stock options and limiting eligibility to employees qual...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.